Cargando…

Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara

Zika virus (ZIKV) is a mosquito-borne flavivirus whose infection in pregnant women is associated with a spectrum of birth defects, which are together referred as Congenital Zika Syndrome. In addition, ZIKV can also induce Guillain–Barré syndrome, which is an autoimmune disease with neurological symp...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez de Oya, Nereida, Pérez, Patricia, Blázquez, Ana-Belén, Escribano-Romero, Estela, Esteban, Mariano, Saiz, Juan-Carlos, García-Arriaza, Juan, Martín-Acebes, Miguel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955905/
https://www.ncbi.nlm.nih.gov/pubmed/35337151
http://dx.doi.org/10.3390/ph15030354
_version_ 1784676450995011584
author Jiménez de Oya, Nereida
Pérez, Patricia
Blázquez, Ana-Belén
Escribano-Romero, Estela
Esteban, Mariano
Saiz, Juan-Carlos
García-Arriaza, Juan
Martín-Acebes, Miguel A.
author_facet Jiménez de Oya, Nereida
Pérez, Patricia
Blázquez, Ana-Belén
Escribano-Romero, Estela
Esteban, Mariano
Saiz, Juan-Carlos
García-Arriaza, Juan
Martín-Acebes, Miguel A.
author_sort Jiménez de Oya, Nereida
collection PubMed
description Zika virus (ZIKV) is a mosquito-borne flavivirus whose infection in pregnant women is associated with a spectrum of birth defects, which are together referred as Congenital Zika Syndrome. In addition, ZIKV can also induce Guillain–Barré syndrome, which is an autoimmune disease with neurological symptoms. The recent description of the first local infections of ZIKV in the European continent together with the expansion of one of its potential vectors, the Asian tiger mosquito (Aedes albopictus), invite us to be prepared for future outbreaks of ZIKV in this geographical region. However, the antigenic similarities of ZIKV with other flaviviruses can lead to an immune cross-reactivity with other circulating flaviviruses inducing, in some cases, flavivirus-disease exacerbation by antibody-dependent enhancement (ADE) of infection, which is a major concern for ZIKV vaccine development. Until now, West Nile virus (WNV) is the main medically relevant flavivirus circulating in the Mediterranean Basin. Therefore, anticipating the potential scenario of emergency vaccination against ZIKV in areas of Europe where WNV is endemic, in this investigation, we have evaluated the cross-reactivity between WNV and our previously developed ZIKV vaccine candidate based on modified vaccinia virus Ankara (MVA) vector expressing ZIKV structural proteins (MVA-ZIKV). To this end, mice were first immunized with MVA-ZIKV, subsequently challenged with WNV, and then, the ZIKV- and WNV-specific immune responses and protection against WNV were evaluated. Our results indicate low cross-reactivity between the MVA-ZIKV vaccine candidate and WNV and absence of ADE, supporting the safety of this ZIKV vaccine candidate in areas where the circulation of WNV is endemic.
format Online
Article
Text
id pubmed-8955905
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89559052022-03-26 Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara Jiménez de Oya, Nereida Pérez, Patricia Blázquez, Ana-Belén Escribano-Romero, Estela Esteban, Mariano Saiz, Juan-Carlos García-Arriaza, Juan Martín-Acebes, Miguel A. Pharmaceuticals (Basel) Communication Zika virus (ZIKV) is a mosquito-borne flavivirus whose infection in pregnant women is associated with a spectrum of birth defects, which are together referred as Congenital Zika Syndrome. In addition, ZIKV can also induce Guillain–Barré syndrome, which is an autoimmune disease with neurological symptoms. The recent description of the first local infections of ZIKV in the European continent together with the expansion of one of its potential vectors, the Asian tiger mosquito (Aedes albopictus), invite us to be prepared for future outbreaks of ZIKV in this geographical region. However, the antigenic similarities of ZIKV with other flaviviruses can lead to an immune cross-reactivity with other circulating flaviviruses inducing, in some cases, flavivirus-disease exacerbation by antibody-dependent enhancement (ADE) of infection, which is a major concern for ZIKV vaccine development. Until now, West Nile virus (WNV) is the main medically relevant flavivirus circulating in the Mediterranean Basin. Therefore, anticipating the potential scenario of emergency vaccination against ZIKV in areas of Europe where WNV is endemic, in this investigation, we have evaluated the cross-reactivity between WNV and our previously developed ZIKV vaccine candidate based on modified vaccinia virus Ankara (MVA) vector expressing ZIKV structural proteins (MVA-ZIKV). To this end, mice were first immunized with MVA-ZIKV, subsequently challenged with WNV, and then, the ZIKV- and WNV-specific immune responses and protection against WNV were evaluated. Our results indicate low cross-reactivity between the MVA-ZIKV vaccine candidate and WNV and absence of ADE, supporting the safety of this ZIKV vaccine candidate in areas where the circulation of WNV is endemic. MDPI 2022-03-15 /pmc/articles/PMC8955905/ /pubmed/35337151 http://dx.doi.org/10.3390/ph15030354 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Jiménez de Oya, Nereida
Pérez, Patricia
Blázquez, Ana-Belén
Escribano-Romero, Estela
Esteban, Mariano
Saiz, Juan-Carlos
García-Arriaza, Juan
Martín-Acebes, Miguel A.
Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
title Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
title_full Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
title_fullStr Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
title_full_unstemmed Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
title_short Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
title_sort low immune cross-reactivity between west nile virus and a zika virus vaccine based on modified vaccinia virus ankara
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955905/
https://www.ncbi.nlm.nih.gov/pubmed/35337151
http://dx.doi.org/10.3390/ph15030354
work_keys_str_mv AT jimenezdeoyanereida lowimmunecrossreactivitybetweenwestnilevirusandazikavirusvaccinebasedonmodifiedvacciniavirusankara
AT perezpatricia lowimmunecrossreactivitybetweenwestnilevirusandazikavirusvaccinebasedonmodifiedvacciniavirusankara
AT blazquezanabelen lowimmunecrossreactivitybetweenwestnilevirusandazikavirusvaccinebasedonmodifiedvacciniavirusankara
AT escribanoromeroestela lowimmunecrossreactivitybetweenwestnilevirusandazikavirusvaccinebasedonmodifiedvacciniavirusankara
AT estebanmariano lowimmunecrossreactivitybetweenwestnilevirusandazikavirusvaccinebasedonmodifiedvacciniavirusankara
AT saizjuancarlos lowimmunecrossreactivitybetweenwestnilevirusandazikavirusvaccinebasedonmodifiedvacciniavirusankara
AT garciaarriazajuan lowimmunecrossreactivitybetweenwestnilevirusandazikavirusvaccinebasedonmodifiedvacciniavirusankara
AT martinacebesmiguela lowimmunecrossreactivitybetweenwestnilevirusandazikavirusvaccinebasedonmodifiedvacciniavirusankara